In summary, our findings suggest that therapeutically inhibiting TIGAR could represent a plausible strategy to hypersensitize hrHPV+ tumor cells to otherwise sub-inhibitory concentrations of chemotherapy agents that cause oxidative stress and DNA-damage and, consequently, reduce the risks of adverse clinical side-effects associated with these anticancer medications. This evidence concerns the gene TIGAR and neoplasm.